作者
Zein Assad,Anne‐Sophie Romain,Camille Aupiais,Mickaël Shum,Cécile Schrimpf,Mathie Lorrot,Harriet Corvol,Blandine Prévost,Charlène Ferrandiz,Anna Giolito,Zaba Valtuille,Matthieu Bendavid,Jérémie F. Cohen,Julie Toubiana,Loïc de Pontual,Camille F. Delande,Michael L. Levy,Perrine See,Robert Cohen,Corinne Lévy,François Angoulvant,Léa Lenglart,Maud Gits‐Muselli,Valérie Biran,Kadiatou Diallo,Oluwafunmilola Alemede,Mohamed M. El Hebil,Xavier Durrmeyer,Géraldine Labouret,Natacha Casanovas,Benjamin Hallak,Olympe Maréchal,Camille Jung,C. Bréhin,Naïm Ouldali
摘要
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.
薰硝壤
热心市民小红花
无限幻悲
张三坟
不懈奋进
8R60d8
坚强的广山
InfoNinja
pluto
shinysparrow
iNk
pcr163
嗯哼
哈哈
Singularity
所所
汉堡包
田様
慕青
寻道图强
皖公网安备34019202002308
